These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15708524)

  • 21. Medical innovation and patent gridlock.
    James JS
    AIDS Treat News; 2005 May; (412):6-8. PubMed ID: 16050004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sanofi takeover jeopardizes Aventis biotech deals.
    Mitchell P
    Nat Biotechnol; 2004 Jun; 22(6):639-40. PubMed ID: 15175667
    [No Abstract]   [Full Text] [Related]  

  • 23. An audience with... Darren Carroll. Interview by Joanna Owens.
    Carroll D
    Nat Rev Drug Discov; 2007 May; 6(5):340. PubMed ID: 17539054
    [No Abstract]   [Full Text] [Related]  

  • 24. Back to the future.
    Offit P
    Expert Rev Vaccines; 2004 Apr; 3(2):107-8. PubMed ID: 15056035
    [No Abstract]   [Full Text] [Related]  

  • 25. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 26. 400 percent ritonavir price hike.
    Alcorn K
    IAPAC Mon; 2004 Jan; 10(1):6-7. PubMed ID: 15108670
    [No Abstract]   [Full Text] [Related]  

  • 27. Creation of a de novo, pharmaceutical company with a urological bent.
    Wyllie MG
    BJU Int; 2011 Nov; 108(9):E310-1. PubMed ID: 22023062
    [No Abstract]   [Full Text] [Related]  

  • 28. On salvaging the pharmaceutical sciences in Canada?
    Jamali F; Pasutto FM
    J Pharm Pharm Sci; 1999; 2(2):36-7. PubMed ID: 10952766
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drug industry is not to be subsidized by the society].
    Melander A
    Lakartidningen; 2004 Feb; 101(7):613; author reply 613. PubMed ID: 15024879
    [No Abstract]   [Full Text] [Related]  

  • 30. GAO report says drug R & D costs rising, innovation decreasing.
    Consult Pharm; 2007 Mar; 22(3):257-8. PubMed ID: 17691159
    [No Abstract]   [Full Text] [Related]  

  • 31. The real cost of development.
    GMHC Treat Issues; 2001; 15(7-8):16. PubMed ID: 11548510
    [No Abstract]   [Full Text] [Related]  

  • 32. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
    Sonderholm J
    J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products.
    Nat Rev Drug Discov; 2008 Nov; 7(11):881. PubMed ID: 18974745
    [No Abstract]   [Full Text] [Related]  

  • 35. BIO 2006 Annual International Convention. The current state of the global biotechnology industry.
    Zarkowska T
    IDrugs; 2006 Jun; 9(6):381-2. PubMed ID: 16752301
    [No Abstract]   [Full Text] [Related]  

  • 36. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

  • 38. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misleading congress about drug development: Reply.
    Dimasi JA; Hansen RW; Grabowski HG
    J Health Polit Policy Law; 2008 Apr; 33(2):319-24; discussion 325-7. PubMed ID: 18325904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.